NOVC.DE

Novo Nordisk A/S [NOVC.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NOVC.DE Stock Summary

In the News

NOVC.DE Financial details

Company Rating
-
Market Cap
406.69B
Income
75.31B
Revenue
214.49B
Book val./share
-
Cash/share
-
Dividend
11.15
Dividend %
1.63%
Employees
59.34K
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
22.78
Forward P/E
-
PEG
6.15
P/S
15.08
P/B
16.93
P/C
-
P/FCF
44.98
Quick Ratio
0.68
Current Ratio
0.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
28.49
EPS next Y
-
EPS next Q
-
EPS this Y
17.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9%
Revenue last 5Y
9.61%
Revenue Q/Q
8.16%
EPS Q/Q
-41.97%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
24%
ROE
81%
ROC
0.62%
Gross Margin
84%
Oper. Margin
38%
Profit Margin
33%
Payout
42%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
51.65-185.12
52W High
-
52W Low
-
RSI
-
Rel Volume
0.53
Avg Volume
51.04K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.242117
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

NOVC.DE Financial Performance

NOVC.DE Dividend History

NOVC.DE Frequently Asked Questions

What is Novo Nordisk A/S stock symbol ?

Novo Nordisk A/S is a DK stock and trading under the symbol NOVC.DE

What is Novo Nordisk A/S stock quote today ?

Novo Nordisk A/S stock price is $- today.

Is Novo Nordisk A/S stock public?

Yes, Novo Nordisk A/S is a publicly traded company.

Something similar

Top by Market Cap
AAPL
NVD.DE
BRK-A
EMBASSY.NS
BRH.DE
Same Sector
NECLIFE.NS
AVRO
VCEL
600671.SS
0LB2.L
Check Those
CR
INPSX
RGO.L
DFU.TO
MITUY
Similar Market Cap
6923.T
FROTO.IS
060150.KQ
XONA.DE
UB32.L

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 51.04K
  • Market Capitalization 406.69B
  • Employee 59.34K
  • CEO Mr. Lars Fruergaard Jorgensen
  • Headquarters Bagsvaerd,DK
  • IPO Date 2001-06-07
  • Website https://www.novonordisk.com/

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.